Aurora Cannabis names EVP for global commercial
Aurora Cannabis creates a new EVP Global Commercial role and appoints industry veteran Faris El Refaie to drive its international medical cannabis strategy.
Rhea-AI Filing Summary
Aurora Cannabis Inc. (ACB) reported the appointment of Faris El Refaie as Executive Vice President, Global Commercial, effective September 28, 2026. This is a newly created role overseeing Aurora’s global commercial function for its medical cannabis business across Canada, Europe, Australia, New Zealand and other international markets.
El Refaie brings 25 years of biopharmaceutical leadership with experience at JAMP Pharma Group, GSK and AstraZeneca, covering innovative medicines, oncology, specialty care, vaccines and consumer healthcare. Aurora states that this appointment supports its strategy to strengthen and accelerate commercial capabilities and expand its global medical cannabis footprint.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
forward-looking information regulatory
medical cannabis medical
GMP-certified technical
global commercial function financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What executive leadership change did ACB announce in this Form 6-K?
When will Faris El Refaie start his role at Aurora Cannabis (ACB)?
What is the scope of the new EVP, Global Commercial role at ACB?
What experience does Faris El Refaie bring to Aurora Cannabis (ACB)?
How does this appointment relate to Aurora Cannabis’s global strategy?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File No. 001-38691
AURORA
CANNABIS INC.
(Translation of registrant's name into English)
2207 90B St. SW
Edmonton, Alberta T6X 1V8
Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☐ Form 40-F ☒
SUBMITTED HEREWITH
| Exhibits | Description | |
| 99.1 | News release dated September 9, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AURORA CANNABIS INC.
/s/ Miguel Martin
Miguel Martin
Chief Executive Officer
Date: September 9, 2026
Exhibit 99.1
Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
EDMONTON, AB, Sept. 9, 2026 /CNW/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a biopharmaceutical leader with 25 years of experience, will join the company as Executive Vice President, Global Commercial, effective September 28, 2026.
Aurora welcomes Faris El Refaie as EVP, Global Commercial
In this newly created role, Faris will oversee Aurora's global commercial function, with responsibility for furthering the company's medical cannabis market strategy, aligning its global portfolio, growing customer engagement and accelerating commercial capabilities across Canada, Europe, Australia, New Zealand and other international markets as Aurora expands its global footprint.
"We're beyond excited to welcome Faris to Aurora at such a pivotal time in the company's global growth journey," says Miguel Martin, Executive Chairman and CEO of Aurora. "Faris brings decades of executive leadership in the biopharmaceutical industry, with a particular focus on commercial growth and market leadership, that will no doubt be additive to our global strategy and the company's overall ability to lead. At Aurora, we have built a leading global medical cannabis platform grounded in science, quality and patient care. In this newly created executive role, Faris will continue this momentum by strengthening Aurora's presence in key markets to bring high-quality medical cannabis to more patients around the world."
Faris joins Aurora with extensive experience across highly regulated pharmaceutical organizations, spanning innovative medicines, oncology, specialty care, vaccines and consumer healthcare. He has held progressive leadership roles at JAMP Pharma Group, GSK and AstraZeneca, building deep commercial expertise across global markets including Canada, the U.S., Europe and Asia. Throughout his career, Faris has led commercial transformations, global product strategies and cross-functional teams, giving him the experience and perspective to help Aurora build on its strong foundation and unlock new opportunities across its international medical cannabis business.
Faris' appointment reflects Aurora's continued focus on strengthening its global commercial platform as the Company expands its leadership across established and emerging international medical cannabis markets in service of Aurora's purpose of Opening the World to Cannabis™.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the appointment of a new EVP Global Commercial; plans for the commercial acceleration of the Company's global medical cannabis business; the Company's focus on furthering its medical cannabis market strategy, aligning the Company's global portfolio, growing customer engagement and accelerating commercial capabilities across Canada, Europe, Australia, New Zealand and other international markets; and statements regarding other growth opportunities.
Forward-looking information or statements contained in this news release have been developed based on the Company and its management's good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company's business and operations in the future. Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things, assumptions about: development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company's operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company's operations; and the Company's ability to conduct operations in a safe, efficient, and effective manner. The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company's business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company's control. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion to revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, and other risks as set out under "Risk Factors" contained in the Annual Information Form dated June 10, 2026 (the "2026 AIF"). Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements. The Company cautions that the list of risks, uncertainties and other factors described in the 2026 AIF is not exhaustive and other factors could also adversely affect its results. Although the Company believes that the expectations conveyed by the forward-looking statements are reasonable based on the information available to the Company on the date hereof, no assurance can be given as to future results, approvals or achievements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-appoints-seasoned-biopharmaceutical-executive-to-lead-commercial-acceleration-of-global-medical-cannabis-business-302872956.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2026/09/c1603.html
%CIK: 0001683541
For further information: For Media: Michelle Lefler | VP, Communications & PR | media@auroramj.com; For Investors: ICR, Inc. | aurora@icrinc.com
CO: Aurora Cannabis Inc.
CNW 07:05e 09-SEP-26